KALEHUA CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F
DALLAS, DELAWARE
CIK 0002106181
· CRD 325290
· Exempt reporting adviser
$132.4M Reported Value Total
Exempt Reporting Adviser
kalehuacapital.com
Source: Form ADV filed 2026-03-31
Reported value
$132.4M
Quarter over quarter
-9.1%
Holdings
22
Top-10 concentration
80.8%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Tai-Li Chang
Managing Director
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 13, 2026 |
| Form | 13F-HR |
| Reported value | $132.4M |
| Positions | 22 |
| Change in reported value | -23.9% |
| New positions | 8 |
| Exited positions | 12 |
| Position turnover | 58.8% |
| Top-10 concentration | 80.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
22 | $132.4M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $174.0M |
|
Q1 2026 13F
Filed May 15, 2026
|
25 | $141.3M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
19 | $101.1M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MANE VERADERMICS INC | $17.7M | 13.34% |
| 2 | BOXX EA SERIES TRUST | $17.6M | 13.28% |
| 3 | KRSA KORSANA BIOSCIENCES INC | $14.2M | 10.7% |
| 4 | XFOR X4 PHARMACEUTICALS INC | $10.8M | 8.15% |
| 5 | ACRS ACLARIS THERAPEUTICS INC | $9.6M | 7.28% |
| 6 | SRZN SURROZEN INC | $9.2M | 6.95% |
| 7 | IKT INHIBIKASE THERAPEUTICS INC | $7.9M | 5.93% |
| 8 | SEPN SEPTERNA INC | $7.6M | 5.75% |
| 9 | BETRF BETTERLIFE PHARMA INC | $6.7M | 5.04% |
| 10 | OBX OBSIDIAN THERAPEUTICS INC | $5.7M | 4.32% |
| 11 | IFRX INFLARX NV | $5.3M | 3.97% |
| 12 | KRRO KORRO BIO, INC | $4.7M | 3.54% |
| 13 | ATTO ATTOVIA THERAPEUTICS INC | $3.4M | 2.59% |
| 14 | DMRA DAMORA THERAPEUTICS INC | $3.0M | 2.23% |
| 15 | QURE UNIQURE NV | $1.9M | 1.45% |
| 16 | GOSS GOSSAMER BIO INC | $1.7M | 1.25% |
| 17 | MIST MILESTONE PHARMACEUTICALS IN | $1.4M | 1.08% |
| 18 | ATHA LEONABIO INC | $1.4M | 1.06% |
| 19 | RNA ATRIUM THERAPEUTICS INC | $932.8K | 0.7% |
| 20 | TIL INSTIL BIO INC | $721.1K | 0.54% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.